BioCartilage -A-4 Cartilage

BioCartilage -A-4 Cartilage (also known as Sigumir) is a natural peptide bioregulator complex extracted from the cartilage and bone tissues of young animals. It belongs to the Cytomax class of tissue-specific peptide bioregulators developed through research associated with the St. Petersburg Institute of Bioregulation and Gerontology.

Each capsule typically contains 40 mg of Peptide Complex A-4 (cartilage peptides). These short-chain peptides are designed to support the metabolic processes of cartilage cells (chondrocytes) and help maintain the health of joints and the spinal column.

Unlike surgical scaffolds or synthetic compounds, BioCartilage A-4 is an oral dietary supplement intended for research and wellness support focused on musculoskeletal tissue.

How BioCartilage A-4 Works

As people age or experience physical stress, natural peptide levels in cartilage tissue can decline. This may contribute to slower tissue repair, reduced flexibility, and increased risk of degenerative changes in joints and the spine.

BioCartilage A-4 provides tissue-specific peptides that may:

• Help normalize metabolism within cartilage cells
• Support protein synthesis inside target cells
• Contribute to the regulation of functions in the spinal column and joints
• Promote regenerative processes in bone and cartilage tissues

Key Potential Benefits of BioCartilage A-4 Cartilage

Research and product literature highlight several areas of support:

• Cartilage metabolism support — Helps normalize cellular processes in cartilage tissue
• Joint comfort and flexibility — May assist in reducing discomfort and improving mobility when used as part of a broader wellness approach
• Spine and musculoskeletal health — Supports regulation of spinal column and joint functions
• Tissue regeneration — Contributes to natural healing processes in bone and cartilage
• Age-related joint concerns — Often positioned for individuals concerned about arthritis, osteochondrosis, osteoporosis, rheumatism, or general wear-and-tear

Who May Benefit from BioCartilage A-4?

BioCartilage A-4 is frequently considered by:

• Adults over 35 experiencing joint or back discomfort
• Individuals with physically demanding jobs or high-impact activity levels
• Those with limited movement or sedentary lifestyles
• People seeking preventative support for long-term joint and bone health
• Seniors, including post-menopausal women concerned about bone density and cartilage integrity

Suggested Use and Dosage

Standard protocol (common recommendations):

• Take 1–2 capsules, 1–2 times daily with meals
• Intensive course: 30 days (often using a 60-capsule pack)
• Maintenance: 10-day courses every 4–6 months (20-capsule packs)

Important notes:

• Not recommended during pregnancy or breastfeeding
• Avoid if sensitive to any ingredients
• Store in a dry, dark place at +2°C to +25°C
• Shelf life is typically 3 years from production

Product Composition and Quality

• Active ingredient: Peptide complex A-4 (cartilage peptides) – 40 mg per capsule
• Other ingredients: Microcrystalline cellulose, calcium stearate, hydroxypropyl methylcellulose (capsule)
• Gluten-free and non-GMO
• Available in 20-capsule (short course) and 60-capsule (full course) packs

BioCartilage A-4 vs. Other Joint Support Options

Frequently Asked Questions

Is BioCartilage A-4 the same as Arthrex BioCartilage? No. Arthrex BioCartilage is a micronized allograft extracellular matrix used surgically to augment microfracture procedures. BioCartilage A-4 (Sigumir) is an oral peptide bioregulator supplement.

How long until results may be noticed? Cartilage responds slowly. Many users follow full 30-day courses, with maintenance cycles. Individual responses vary.

Can it be combined with other bioregulators? It is sometimes used alongside vessel or muscle bioregulators for broader musculoskeletal support. Consult a qualified practitioner.

Is there strong clinical evidence? Evidence is primarily based on the broader body of peptide bioregulator research and product literature. Large-scale independent randomized controlled trials specifically on the Sigumir capsule formulation remain limited.